Our global life sciences company brings diagnostic testing & drug development together.

NASH FibroSure®

CPT: [MAAA: 0003M] or 82172; 82247; 82465; 82947; 82977; 83010; 83883; 84450; 84460; 84478
Print Share


  • Fatty Liver Disease
  • Nonalcoholic Fatty Liver Disease
  • Noninvasive Liver Biopsy
  • Steatohepatitis

Special Instructions

The patient's age, gender, height, and weight at the time of collection must be submitted for FibroSure® testing.

Expected Turnaround Time

3 - 6 days

Related Documents

For more information, please review the literature below.

NAFLD-NASH Capabilities Brochure

Specimen Requirements




3.5 mL

Minimum Volume

2 mL


Red-top tube or gel-barrier tube


Separate serum from cells within two hours of collection.

Storage Instructions

Specimen can be stored refrigerated at 2°C to 8°C for 72 hours and frozen at -70°C for seven days. Frozen samples are stable for one freeze/thaw cycle.

Patient Preparation

Patient should be fasting for at least eight hours.

Causes for Rejection

Gross hemolysis; gross lipemia; improper labeling; nonfasting specimen; patient younger than 14 years of age

Test Details


This test is a noninvasive assessment of liver status in patients with nonalcoholic fatty liver disease (NAFLD). Quantitative results of 10 biochemicals in combination with age, gender, height, and weight are analyzed using a computational algorithm to provide a quantitative surrogate marker (0.0-1.0) of liver fibrosis (Metavir F0-F4), hepatic steatosis (0.0-1.0, S0-S3), and nonalcoholic steatohepatitis (NASH) (0.0-0.75, N0-N2). The absence of steatosis (S<0.38) precludes the diagnosis of NASH.


NASH FibroSure® is recommended for patients with suspected nonalcoholic fatty liver disease. It is not recommended for patient with other liver diseases. It is also not recommended in patients with Gilbert disease, acute hemolysis, acute hepatitis, acute inflammation of the liver, autoimmune hepatitis, extrahepatic cholestasis, transplant patients, and/or renal insufficiency patients. Any of these clinical situations may lead to inaccurate quantitative predictions of fibrosis.

This test was developed, and its performance characteristics determined, by LabCorp. It has not been cleared or approved by the US Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary.


Poynard T, Ratziu V, Charlotte F, et al. Diagnostic value of biochemical markers (NashTest) for the prediction of non-alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol. 2006 Nov 10, 6:34. 17096854
Poynard T, Ratziu V, Naveau S, et al. The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Comp Hepatol. 2005 Dec 23; 4:10. 16375767
Ratziu V, Massard J, Charlotte F, et al. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol. 2006; 6:6. 16503961


Order Code Order Code Name Order Loinc Result Code Result Code Name UofM Result LOINC
550140 NASH FibroSure 550147 Fibrosis Score 48795-9
550140 NASH FibroSure 550148 Fibrosis Stage 48794-2
550140 NASH FibroSure 550149 Steatosis Score n/a
550140 NASH FibroSure 550153 Steatosis Grade n/a
550140 NASH FibroSure 550157 NASH Score 48792-6
550140 NASH FibroSure 550142 NASH Grade 48793-4
550140 NASH FibroSure 550155 Height: in 3137-7
550140 NASH FibroSure 550156 Weight: LBS 3141-9
550140 NASH FibroSure 122137 Alpha 2-Macroglobulins, Qn mg/dL 1835-8
550140 NASH FibroSure 001629 Haptoglobin mg/dL 4542-7
550140 NASH FibroSure 016874 Apolipoprotein A-1 mg/dL 1869-7
550140 NASH FibroSure 001100 Bilirubin, Total mg/dL 1975-2
550140 NASH FibroSure 001960 GGT IU/L 2324-2
550140 NASH FibroSure 001547 ALT (SGPT) P5P IU/L 1743-4
550140 NASH FibroSure 001125 AST (SGOT) P5P IU/L 30239-8
550140 NASH FibroSure 001067 Cholesterol, Total mg/dL 2093-3
550140 NASH FibroSure 001036 Glucose, Serum mg/dL 2345-7
550140 NASH FibroSure 001175 Triglycerides mg/dL 2571-8
550140 NASH FibroSure 550143 Interpretations: n/a
550140 NASH FibroSure 550107 Fibrosis Scoring: n/a
550140 NASH FibroSure 550189 Steatosis Grading n/a
550140 NASH FibroSure 550144 NASH Scoring n/a
550140 NASH FibroSure 550158 Limitations: 8251-1
550140 NASH FibroSure 550154 Comment: 77202-0
550140 NASH FibroSure 123097 Comment: 77202-0

For Providers

Please login to order a test

Order a Test

© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.

CPT Statement/Profile Statement

The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at Additional information regarding LOINC® codes can be found at, including the LOINC Manual, which can be downloaded at